Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
Study Identifier
223575-002
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 2
Sex
Female & Male
Age
18+ years
Protocol Summary
This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.
Study Locations
Location
Status
Location
Arizona Center for Clinical Trials
Phoenix, Arizona, United States, 85003
Status
Not applicable
Location
Specialty Eye Ctr. Med. Group
Glendale, California, United States, 91203
Status
Not applicable
Location
The Eye Research Foundation
Newport Beach, California, United States, 92663
Status
Not applicable
Location
WCCT Global
Santa Ana, California, United States, 92705
Status
Not applicable
Location
Eye Associates of Colorado Springs
Colorado Springs, Colorado, United States, 80909
Status
Not applicable
Location
West Coast Eye Institute
Lecanto, Florida, United States, 34491
Status
Not applicable
Showing {first} - {last} of {total} Results